Reconsidering the connection between vitamin D levels and age-related macular degeneration

Eye

Volumn 25, Issue 9, 2011, Pages 1122-1129

  Golan, S ^a,c   Shalev, V ^b,c   Treister, G ^b,c   Chodick, G ^b   Loewenstein, A ^a,c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b MACCABI HEALTHCARE SERVICES   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

age related macular degeneration; Health Maintenance Organization; Maccabi Healthcare Services; serum 25 OH vitamin D

Indexed keywords

VITAMIN D;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CONTINUING EDUCATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; INFLAMMATION; ISRAEL; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; PREVALENCE; PUBLICATION; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; VITAMIN BLOOD LEVEL;

EID: 80052639810     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.174     Document Type: Article

References (53)

1. Age-Related Eye Disease Study Research Group. A randomized, placebo controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-1436.
2. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137: 486-495. (Pubitemid 38328641)
3. Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5-year incidence of age-related maculopathy: The Blue Mountains Eye Study. Arch Ophthalmol 2002; 120: 1357-1363. (Pubitemid 36105441)
4. Klein ML, Mauldin WM, Stoumbos VD. Heredity and age-related macular degeneration: Observations in monozygotic twins. Arch Ophthalmol 1994; 112: 932-937. (Pubitemid 24228253)
5. Taylor HR, West S, Muñoz B, Rosenthal FS, Bressler SB, Bressler NM. The longterm effects of visible light on the eye. Arch Ophthalmol 1992; 110: 99-104.
6. Mares J. Carotenoids and eye disease: Epidemiologic evidence. In: Krinsky NI, Mayne S (eds). Carotenoids in Health and Disease. Marcel Dekker Inc: New York, NY, 2003, p 19.
7. Mares-Perlman JA, Millen AE, Ficek TL, Hankinson SE. The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease. J Nutr 2002; 132: 518S-524S. (Pubitemid 34208762)
8. Mares-Perlman JA, Brady WE, Klein R, VandenLangenberg GM, Klein BE, Palta M. Dietary fat and age-related maculopathy. Arch Ophthalmol 1995; 113: 743-748.
9. Seddon JM, Rosner B, Sperduto RD, Yannuzzi L, Haller JA, Blair NP et al. Dietary fat and risk for advanced agerelated macular degeneration. Arch Ophthalmol 2001; 119: 1191-1199. (Pubitemid 32730008)
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431. (Pubitemid 44511557)
11. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 2000; 70: 441-449. (Pubitemid 30662042)
12. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 2001; 73: 887-896. (Pubitemid 34112114)
13. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134: 411-431.
14. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20: 705-732. (Pubitemid 32918285)
15. Dastgheib K, Green W. Granulomatous reaction to Bruch's membrane in age related macular degeneration. Arch Ophthalmol 1994; 112: 813-818. (Pubitemid 24180520)
16. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR et al. The pivotal role of the complement system in aging and age related macular degeneration: Hypothesis re-visited. Prog Retin Eye Res 2010; 29: 95-112.
17. Augustin AJ, Kirchhof J. Inflammation and the pathogenesis of age related macular degeneration. Expert Opin Ther Targets 2009; 13: 641-651.
18. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122: 598-614. (Pubitemid 38456297)
19. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: The Blue Mountains Eye Study. Arch Ophthalmol 1998; 116: 583-587. (Pubitemid 28414571)
20. Seregard S, Algvere PV, Berglin L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol 1994; 232: 325-329. (Pubitemid 24222135)
21. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. Association of emphysema, gout, and inflammatory markers with long-term incidence of age-related maculopathy. Arch Ophthalmol 2003; 121: 674-678. (Pubitemid 36554470)
22. Hutchinson AK, Grossniklaus HE, Capone A. Giant-cell reaction in surgically excised subretinal neovascular membrane. Arch Ophthalmol 1993; 111: 734-735. (Pubitemid 23170581)
23. Topilski I, Flaishon L, Naveh Y, Harmelin A, Levo Y, Shachar I. The anti-inflammatory effects of 1,25- dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing. Eur J Immunol 2004; 34: 1068-1076. (Pubitemid 39255985)
24. Thomasset M. Vitamin D and the immune system [in French]. Pathol Biol (Paris) 1994; 42: 163-172.
25. Manolagas SC, Provvedini DM, Murray EJ, Tsoukas CD, Deftos LJ. The antiproliferative effect of calcitriol on human peripheral blood mononuclear cells. J Clin Endocrinol Metab 1986; 63: 394-400. (Pubitemid 16035687)
26. Müller K, Gram J, Bollerslev J, Diamant M, Barington T, Hansen MB et al. Down-regulation of monocyte functions by treatment of healthy adults with 1 alpha,25 dihydroxyvitamin D3. Int J Immunopharmacol 1991; 13: 525-530.
27. Takahashi K, Horiuchi H, Ohta T, Komoriya K, Ohmori H, Kamimura T. 1 Alpha,25-dihydroxyvitamin D3 suppresses interleukin-1beta-induced interleukin-8 production in human whole blood: An involvement of erythrocytes in the inhibition. Immunopharmacol Immunotoxicol 2002; 24: 1-15. (Pubitemid 34496732)
28. Lefebvre d'Hellencourt C, Montero-Menei CN, Bernard R, Couez D. Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production by the EOC13 microglial cell line. J Neurosci Res 2003; 71: 575-582. (Pubitemid 36158342)
29. D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3: Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101: 252-262. (Pubitemid 28058925)
30. Holick MF. Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004; 79: 362-371. (Pubitemid 41115577)
31. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand) 2003; 49: 277-300.
32. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the IowaWomen's Health Study. Arthritis Rheum 2004; 50: 72-77. (Pubitemid 38084289)
33. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: Mechanisms for inflammatory damage in chronic disorders? Q J Med 2002; 95: 787-796. (Pubitemid 36032948)
34. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002; 143: 2508-2514. (Pubitemid 34701313)
35. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1995; 36: 83-87.
36. Iseki K, Tatsuta M, Uehara H, Iishi H, Yano H, Sakai N et al. Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1999; 81: 730-733. (Pubitemid 29214382)
37. Gunter EWLB, Koncikowski SM. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey, 1988-1994: NHANES III Reference Manuals and Reports. Centers for Disease Control and Prevention: Hyattsville, MD, 1996.
38. 25-hydroxyvitamin D 125I RIA kit instruction manual (68100E). DiaSorin Inc.: Stillwater, MN, 2004.
39. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 7227-7232. (Pubitemid 40696361)
40. Despriet DD, Klaver CC,Witteman JC, Bergen AA, Kardys I, de Maat MP et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006; 296: 301-309. (Pubitemid 44079314)
41. Zareparsi S, Branham KE, Li M, Shah S, Klein RJ, Ott J et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 2005; 77: 149-153. (Pubitemid 40848046)
42. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-389. (Pubitemid 40530070)
43. Sepp T, Khan JC, Thurlby DA, Shahid H, Clayton DG, Moore AT et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci 2006; 47: 536-540. (Pubitemid 46768378)
44. Gorin MB. A clinician's view of the molecular genetics of age-related maculopathy. Arch Ophthalmol 2007; 125: 21-29. (Pubitemid 46072372)
45. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: Prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 2005; 123: 774-782. (Pubitemid 41056598)
46. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA 2004; 291: 704-710. (Pubitemid 38543790)
47. Klein R, Klein BE, Marino EK, Kuller LH, Furberg C, Burke GL et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology 2003; 110: 25-33. (Pubitemid 36068722)
48. Parekh N, Chappell RJ, Millen AE, Albert DM, Mares JA. Association between vitamin D and age-related macular degeneration in the Third National Health and Nutrition Examination Survey, 1988 through 1994. Arch Ophthalmol 2007; 125(5): 661-669. (Pubitemid 46762728)
49. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration f: Association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 2003; 121(12): 1728-1737. (Pubitemid 37517440)
50. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: The US Twin Study of Age Related Macular Degeneration. Arch Ophthalmol 2006; 124(7): 995-1001. (Pubitemid 44036322)
51. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168(15): 1629-1637.
52. Tandeter H, Grynbaum M, Zuili I, Shany S, Shvartzman P. Serum 25-OH vitamin D levels in patients with fibromyalgia. Isr Med Assoc J 2009; 11: 339-342.
53. National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Fact Sheet: Vitamin D, 2011.